Stanford researchers have developed a pioneering gene therapy by targeting reactive astrocytes in the optic nerve head (ONH) and modulating cyclic adenosine monophosphate (cAMP) levels for targeted treatment of glaucoma and other retinal disorders.
To manage the development and progression of glaucoma, researchers at Stanford University have developed a biocompatible suprachoroidal spacer implant.
Researchers at Stanford have developed a new therapeutic to promote survival of retinal ganglion cells (RGCs) and optic nerve regeneration after traumatic injury or optic neuropathies.